Preliminary quarterly sales figures for Vykat surpassed Wall Street estimates, but shares fell on concerns the company may not be courting a buyer.
Soleno sales of new Prader-Willi drug rise faster than expected
Preliminary quarterly sales figures for Vykat surpassed Wall Street estimates, but shares fell on concerns the company may not be courting a buyer.